Also Known As: Fluticasone/Salmeterol, Advair, Seretide, Viani, Adoair, Foxair
The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (in the US and Canada), Seretide (India, Australia, Colombia, EU, México, New Zealand, South Africa, South Korea, UK), Viani (Germany), Adoair (Japan) and Foxair (South Africa). Annual worldwide sales were approximately $7B in 2009. Patent protection in the US expired in 2010, and European patent protection will expire in 2013. However, the availability of a generic form of Advair in the United States may be significantly delayed in the US because the Food and Drug Administration has not determined a standard for the bioequivalence of inhaled steroids in multi-dose inhalers or dry powder inhalers.
Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination, while salmeterol treats constriction of the airways. Together, they relieve the symptoms of coughing, wheezing and shortness of breath.